$RVMD · Revolution Medicines, Inc.

Revolution Medicines drew the $250M Tranche A Loan under its Royalty Pharma loan agreement, triggered by FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma. The loan carries interest at 3-month Term SOFR (floor 3.50%) + 5.75%, matures October 2032, and required a $5M draw fee. Separately, the company elected not to exercise its Tranche 3 royalty sale option, forgoing up to $250M in proceeds and retaining full revenue participation rights on RASONQUE.

Extended-hours trading shows minimal reaction at $188.44, essentially flat vs the regular close. The $250M draw was fully expected given the FDA approval trigger; the decision to decline the Tranche 3 royalty sale signals management confidence in RASONQUE's commercial prospects and a preference to retain revenue rights rather than monetize them.

The decision to decline $250M in non-dilutive royalty capital signals management's conviction in RASONQUE's commercial trajectory and willingness to retain full drug economics.

Royalty Pharma's structured financing — combining a senior secured loan with an optional revenue participation right — mirrors the hybrid capital strategies increasingly used by pre-commercial and early-commercial biotechs to fund launches without pure equity dilution.

The Tranche A Loan's floating rate (SOFR + 5.75%) exposes the company to rising interest costs. Prepayment penalties of up to 3% plus make-whole amounts apply before year three, limiting refinancing flexibility.